ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

CordenPharma extends oligonucleotides in Colorado

by Rick Mullin
May 13, 2018 | APPEARED IN VOLUME 96, ISSUE 20

09620-buscon14-cordencxd.jpg
Credit: CordenPharma
A view inside CordenPharma's expanded facility.

CordenPharma has expanded oligonucleotide active pharmaceutical ingredient manufacturing capacity at its Boulder, Colo., plant. The German company, which purchased the site from Roche in 2011, says the facility now can synthesize up to 500 kg of oligonucleotides per year, making it one of the world’s largest oligonucleotide manufacturing sites.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment